



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/596,731	Susanne Alenfalk	ASZN0107-100(101340-1PUS)
INTERNATIONAL APPLICATION NO.		
PCT/SE04/01960		
I.A. FILING DATE		PRIORITY DATE
12/21/2004		12/23/2003
CONFIRMATION NO. 9947 371 FORMALITIES LETTER *OC000000023176068*		

Date Mailed: 04/02/2007

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 06/22/2006
- Copy of the International Search Report filed on 06/22/2006
- Preliminary Amendments filed on 06/22/2006
- Information Disclosure Statements filed on 11/16/2006
- Oath or Declaration filed on 11/16/2006
- Request for Immediate Examination filed on 06/22/2006
- U.S. Basic National Fees filed on 06/22/2006
- Assignment filed on 09/08/2006
- Priority Documents filed on 06/22/2006
- Power of Attorney filed on 11/16/2006
- Specification filed on 06/22/2006
- Claims filed on 06/22/2006
- Abstracts filed on 06/22/2006

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$250** for a Large Entity:

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and

a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- The fee for electronically submitting a specification and drawing containing more than 100 pages has not been paid in full. Applicant owes \$250 for 33 pages in excess of 150 pages for a large entity.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
-----------------------------	-------------------------------	------------------

ASZN0107-100(101340-

10/596,731

PCT/SE04/01960

1PUS)

FORM PCT/DO/EO/905 (371 Formalities Notice)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Susanne Alenfalk et al.**

Serial No.: **10/596,731**

Group Art Unit: **To Be Determined**

Filing Date: **To Be Determined**

Examiner: **To Be Determined**

For: **DIPHENYLAZETIDINONE DERIVATIVES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION

Dear Sir:

In response to the Notification of Missing Requirements dated April 2, 2007 in connection with the above-identified patent application, Applicant has reviewed the Specification and believes the application does not contain any nucleotide and/or amino acid sequences that would be subject to listing in a Sequence Listing and respectfully requests that the pages allegedly containing such sequences be identified, or the objection be withdrawn.

We note the Declaration filed on November 16, 2006 has been entered into the subject File Wrapper. The Commissioner is hereby authorized to charge any additional fees or credit any over payment to Deposit Account No. 50-0436.

Respectfully submitted,

/Paul K. Legaard, Reg. #38,534/
Paul K. Legaard
Registration No. 38,534

Date: May 16, 2007

Pepper Hamilton LLP
500 Grant Street, 50th Floor
Pittsburgh, PA 15219
Tel: 610.640.7855
Fax: 610.640.7835